Design Therapeutics Inc. (NASDAQ: DSGN) Stock Information | RedChip

Design Therapeutics Inc. (NASDAQ: DSGN)


$6.2700
+0.0600 ( +0.80% ) 10.6K

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Market Data


Open


$6.2700

Previous close


$6.2100

Volume


10.6K

Market cap


$347.37M

Day range


$6.1150 - $6.2650

52 week range


$2.2450 - $7.7700

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 17, 2024
4 Insider transactions 1 Jun 17, 2024
8-k 8K-related 11 Jun 17, 2024
10-q Quarterly Reports 58 May 08, 2024
8-k 8K-related 13 May 08, 2024
ars Annual reports 1 Apr 25, 2024
def Proxies and info statements 5 Apr 25, 2024
4 Insider transactions 1 Mar 25, 2024
4 Insider transactions 1 Mar 25, 2024
3 Insider transactions 2 Mar 20, 2024

Latest News